Past Event

Tackling antimicrobial resistance (AMR)

Pathological microbes are increasingly resistant to antimicrobial treatments. The resulting health crisis is one of the greatest challenges facing society. At this event, Jim O'Neill will present the Independent Review on Antimicrobial Resistance and a panel will discuss how to tackle drug resistance.

Date: July 14, 2016, 12:30 pm Topic: Innovation & Competition Policy

Summary

See below for video and presentation.

The medical community has identified antimicrobial resistance as a major issue for human beings. In fact, drug resistance poses a threat to our future development and prosperity, as well as to our health. According to recent studies, the number of deaths attributable to AMR in 2050 could equal 10 million. The figure is alarming, making the estimated number of AMR deaths larger than the amount of victims attributable to cancer (8.2 million in 2050).

Because of its relevance, the AMR must also be treated as an economic issue, and the Review on Antimicrobial Resistance commissioned by the UK government in 2014 is playing a key role for this purpose. A ten-point plan has been developed in the Review for tackling AMR, with public awareness being on top of the list, since the problem is ignored in our society. In order to fight the issue, information campaigns should be carried out, as most people appear to have no clue of what antimicrobial resistance is and why it represents a huge threat. A rise in public awareness towards antimicrobial resistance would also bring results, if people proactively react to it. In fact, a way to reduce the impact of the problem is increasing sanitation and hygiene, which could be done by individuals and constitutes the most effective way of facing the issue.

The plan to tackle AMR suggests to stop using antibiotics in agriculture, environment and food processing. To this extent, more transparency from food producers and retailers and in the whole agricultural sector is needed. In general, our society has to increase surveillance on how antibiotics are used in these fields as well as in medicine. The reduction in use and prescriptions of antibiotics would limit the evolution of bacteria. Rapid and efficient diagnostics could also help: sometimes antibiotics are not useful in medical treatments, and the abuse in prescriptions can only worsen the issue. Antibiotics should only be prescribed if a diagnostic technique is used to prove to the necessity of their use. As an alternative, the medical community should boost the role of vaccines, which would partly reduce the use of antibiotics.

On the research side, new drugs should be developed, both to treat patients with pharmaceutical products other than antibiotics and to tackle antimicrobial resistance directly. However, this also requires an increase in investments in research and global innovation funding: funds from a multiplicity of international stakeholders should be allocated and spent on research in a coordinated and strategic way. It is important to emphasize that action to tackle AMR should be conducted on a global basis, and support to achieve international agreements on what has to be done is needed.

Just committing resources, however, does not lead to the solution of the problem itself. Efforts from policy makers can play a central role. The scarce attention of policy makers to date regarding AMR can be attributed to the low level of information and a missing economic quantification of the problem, both of which would increase the awareness of policy-makers towards it. Moreover, the European Commission also needs directives to clarify which roles it could play as a stakeholder and policy-maker and how it can act in order to influence global action.

As a final remark, we should keep in mind that if we are able, as a global society, to build up an effective and sustainable model for funding research, the issue of AMR can be handled and its impact reduced.

Event notes by Domenico Favoino, Research Assistant

VIDEO RECORDING


Event Materials

The Review on Antimicrobial Resistance: global solutions to drug-resistant infections | Presentation by Jim O’Neill

 

Speakers

James Anderson

Head of Corporate Government Affairs, GlaxoSmithKline

Sally Davies

Chief Medical Officer for England

Charles Knirsch

Vice President, Therapeutic Vaccines Program Lead, Vaccine Clinical Research and Development, Pfizer

Jim O‘Neill

Xavier Prats Monné

Director General, European Commission, DG SANTE

Karen E. Wilson

Non-resident Fellow

Location & Contact

Bruegel, Rue de la Charité 33, 1210 Brussels

Matilda Sevon

matilda.sevon@bruegel.org

Read about event More on this topic

Past Event

Past Event

The impact of Brexit for Research & Innovation in Europe

This event will feature a new and interactive format, with a restricted and high-level on-site audience and in parallel, it will be livestreamed on our website to remain public and attract the widest participation

Speakers: Alastair Buchan, Matt Dann, David Earnshaw, Kurt Deketelaere, Maryline Fiaschi, Martin Muller, Christian Naczinsky and Reinhilde Veugelers Topic: Innovation & Competition Policy Location: Bruegel, Rue de la Charité 33, 1210 Brussels Date: December 12, 2017
Read about event More on this topic

Past Event

Past Event

Health care and macro-economics in Europe

What are the strengths and challenges of health care systems in each EU country? What are the common policy priorities and opportunities for EU value added?What role do healthcare systems play in public finances and macroeconomic developments? What are the economic values of investing in healthcare?

Speakers: Zsolt Darvas, Caroline Costongs, Per Eckefeldt, Sylvain Giraud, Petra Laux and Xavier Prats Monné Topic: European Macroeconomics & Governance Location: Bruegel, Rue de la Charité 33, 1210 Brussels Date: December 7, 2017
Read about event More on this topic

Past Event

Past Event

Mergers and innovation

At this closed-door, off-the-record event we will discuss the impact that mergers have on innovation.

Speakers: Justus Haucap, Carles Esteva Mosso, Jorge Padilla and Reinhilde Veugelers Topic: Innovation & Competition Policy Location: Bruegel, Rue de la Charité 33, 1210 Brussels Date: November 29, 2017
Read about event More on this topic

Past Event

Past Event

Start-ups' scale-up and innovation

What role is there for policy to address the funding barrier for scaling-up? Do we need a reorientation of the currently pursued policies in European countries?

Speakers: Rudy Aernoudt, Johan Cardoen, François Véron, Reinhilde Veugelers and Louis Papaemmanuel Topic: Innovation & Competition Policy Location: Bruegel, Rue de la Charité 33, 1210 Brussels Date: November 21, 2017
Read about event More on this topic

Past Event

Past Event

Crowd Employment

This event aims to discuss the various nuances and diversity that characterize crowd employment.

Speakers: Cristiano Codagnone, Valerio Michele De Stefano, Irene Mandl, Georgios Petropoulos and Amit Singh Topic: Innovation & Competition Policy Location: Bruegel, Rue de la Charité 33, 1210 Brussels Date: October 5, 2017
Read article Download PDF More by this author

External Publication

An innovation deficit behind Europe’s overall productivity slowdown?

Reinhilde Veugelers' chapter in "Investment and Growth in Advanced Economies", conference volume of the European Central Bank’s Forum on central banking in Sintra.

By: Reinhilde Veugelers Topic: European Macroeconomics & Governance, Innovation & Competition Policy Date: October 2, 2017
Read article More on this topic More by this author

Blog Post

The Economics of Healthcare

Healthcare reform has been a thorn in the side of the US administration for several months, prompting President Trump to declare that “Nobody knew that healthcare could be so complicated.” We review recent economists’ views on the issue.

By: Silvia Merler Topic: Global Economics & Governance Date: October 2, 2017
Read about event More on this topic

Past Event

Past Event

EU-China economic relations: looking to 2025

This event will see the launch of a report on EU-China relations and discuss issues such as trade and investment, industrial cooperation and innovation and global governance

Speakers: Victor Chu, Ian Davis, Alicia García-Herrero, Dame Clara Furse, Tony Graziano, Anatole Kaletsky, K.C. Kwok, Lawrence J. Lau, Ina Lepel, Hanna Müller, André Sapir, Robin Niblett, György Szapáry, Jean-Claude Trichet, Zhang Yansheng, H.E. Ambassador Yang Yanyi, Liu Xiangdong, Gunnar Wiegand, Guntram B. Wolff, Huang Ping and Elena Flores Topic: Global Economics & Governance Location: Bruegel, Rue de la Charité 33, 1210 Brussels Date: September 13, 2017
Read about event

Past Event

Past Event

Bruegel Annual Meetings 2017

The Annual Meetings are Bruegel’s flagship event. They offer a mixture of large public debates and small private sessions about key issues in European and global economics. In a series of high-level discussions, Bruegel’s scholars, members and stakeholders will address the economic policy challenges facing Europe.

Speakers: Carlos Sallé Alonso, José Antonio Álvarez Álvarez, Agnès Bénassy-Quéré, Pervenche Béres, Matthias Buck, Grégory Claeys, Zsolt Darvas, Jean Luc Demarty, Maria Demertzis, Anna Ekström, Lowri Evans, Ferdinando Giugliano, Sandro Gozi, Peter Grünenfelder, Reiner Hoffmann, Levin Holle, Kate Kalutkiewicz, Steffen Kampeter, Peter Kažimír, Emmanuel Lagarrigue, Matti Maasikas, Steven Maijoor, Reza Moghadam, Nathalie Moll, James Murray, Johan Van Overtveldt, Julia Reinaud, André Sapir, Dirk Schoenmaker, Mateusz Szczurek, Marianne Thyssen, Jean-Claude Trichet, Reinhilde Veugelers, Nicolas Véron, Ida Wolden Bache, Liviu Voinea, Guntram B. Wolff and Georg Zachmann Topic: Energy & Climate, European Macroeconomics & Governance, Finance & Financial Regulation, Global Economics & Governance, Innovation & Competition Policy Location: Square - Brussels Meeting Centre Date: September 7, 2017
Read article More on this topic

Blog Post

Low carbon technology exports: the race is still open

A country’s relative strength in exporting a certain product is likely to persist. But it is easier to gain a comparative advantage in exporting low carbon products. When it comes to R+D, strength in a certain technological field is much less linked to past specialisation. This also holds for low carbon technologies. Finally, our preliminary findings are consistent with the view that R+D can help a country specialise in clean technology exports. However, we are not yet able to show that policy action supporting R+D in clean technologies is a sensible way to develop a comparative export advantage in these sectors.

By: Georg Zachmann and Enrico Nano Topic: Innovation & Competition Policy Date: August 24, 2017
Read about event

Past Event

Past Event

Is there a way out of non-performing loans in Europe?

At this event we looked at the issue of non-performing loans in Europe. The event also saw the launch of the latest issue of "European Economy – Banks, Regulation and the Real Sector."

Speakers: Emilios Avgouleas, Giorgio Barba Navaretti, Giacomo Calzolari, Maria Demertzis, Martin Hellwig, Helen Louri and Laura von Daniels Topic: European Macroeconomics & Governance, Finance & Financial Regulation Location: Bruegel, Rue de la Charité 33, 1210 Brussels Date: July 6, 2017
Read article Download PDF More on this topic

External Publication

Review of EU-third country cooperation on policies falling within the ITRE domain in relation to Brexit

What is the possible future relationship between the EU and the UK in light of Brexit? The report provides a critical assessment of the implications of existing models of cooperation between third countries and the European Union on energy, electronic communications, research policy and small business policy.

By: J. Scott Marcus, Georgios Petropoulos, André Sapir, Simone Tagliapietra, Alessio Terzi, Reinhilde Veugelers and Georg Zachmann Topic: European Macroeconomics & Governance Date: July 5, 2017
Load more posts